How J&J’s Ry­bre­vant com­bo stacks up against As­traZeneca’s Tagris­so in EGFR-mu­tat­ed lung can­cer: #ES­MO23

MADRID — John­son & John­son’s com­bi­na­tion treat­ment for a com­mon mu­ta­tion of non-small cell lung can­cer kept can­cer at bay for longer than As­traZeneca’s Tagris­so …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.